Neuroscience
Meta-Analysis
100%
Positive Syndrome
100%
Antipsychotic
100%
Schizophrenia Spectrum Disorder
100%
Negative Syndrome
80%
Ziprasidone
80%
Olanzapine
60%
Risperidone
40%
Extrapyramidal Symptom
40%
Molindone
40%
Placebo
40%
Paliperidone
40%
Triacylglycerol
40%
Clozapine
20%
Blood Plasma
20%
Prolactin
20%
Randomized Controlled Trial
20%
Aripiprazole
20%
Quetiapine
20%
Keyphrases
Network Meta-analysis
100%
Schizophrenia Spectrum Disorders
100%
Antipsychotics
100%
Ziprasidone
40%
Negative Syndrome
40%
Olanzapine
30%
Efficacy Outcomes
20%
Extrapyramidal Symptoms
20%
Placebo
20%
Low-to-moderate
20%
Early-onset Schizophrenia
20%
Akathisia
20%
Risperidone
20%
Cochrane Library
10%
Pairwise Meta-analysis
10%
Trial Data
10%
Grading of Recommendations
10%
Evaluation Approach
10%
Comparative Safety
10%
Reaction Profile
10%
Treatment Discontinuation
10%
Triglyceride Level
10%
Protocol Registration
10%
Metaanalysis
10%
MEDLINE
10%
Sedation
10%
Aripiprazole
10%
Randomized Trial
10%
Adverse Reactions
10%
Positive Symptoms
10%
Comparative Efficacy
10%
Plasma Triglycerides
10%
Symptom Change
10%
Weight Gain
10%
Insomnia
10%
Clozapine
10%
Triglycerides
10%
Assessment Approach
10%
Evaluation Assessment
10%
Assessment Development
10%
Serious Adverse Events
10%
ARM-based
10%
Prolactin
10%
Quetiapine
10%
Randomized Controlled Trial
10%
Random Effects
10%
Safety Outcomes
10%
Development Approach
10%
Pharmacology, Toxicology and Pharmaceutical Science
Positive Syndrome
100%
Antipsychotic
100%
Schizophrenia Spectrum Disorder
100%
Ziprasidone
80%
Negative Syndrome
80%
Olanzapine
60%
Risperidone
40%
Placebo
40%
Adverse Event
40%
Triacylglycerol
40%
Extrapyramidal Symptom
40%
Akathisia
40%
Randomized Controlled Trial
20%
Clozapine
20%
Quetiapine
20%
Aripiprazole
20%
Prolactin
20%